Carlyle is lending $170m to OPT and if the drug fails, they don't require OPT to pay up. If the drug is approved, they get 4x back from the revenue sharing. This is very strong confidence from Carlyle that mkt does not see yet...not just on success in P3 trial but also on commercialization.
I think OPT should be trading at $1bn mkt cap now.
Carlyle is lending $170m to OPT and if the drug fails, they...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.5¢ |
Change
0.005(0.82%) |
Mkt cap ! $407.6M | |||
| Open | High | Low | Value | Volume |
| 60.5¢ | 63.0¢ | 60.5¢ | $5.200M | 8.521M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 82640 | 61.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.5¢ | 9658 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
62.0¢ |
Change
0.005 ( 0.81 %) |
||||
| Open | High | Low | Volume | ||
| 61.0¢ | 62.5¢ | 61.0¢ | 58629 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| OPT (ASX) Chart |